Inspire Medical price target lowered to $220 from $230 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Inspire Medical (INSP) to $220 from $230 and keeps an Overweight rating on the shares. Though revenues for Q4 and 2025 guidance were known following January’s pre-announcement, the firm was “impressed” with Inspire’s “continued outperformance below the topline,” the analyst tells investors. The civil investigative demand from the Department of Justice U.S. Attorney’s Office for the District of Minnesota that the company disclosed is “a mild annoyance but manageable,” the analyst added.